Allogene Therapeutics Inc (ALLO) Stock Price, Quote & News

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 2700

Website: allogene.com

Address:

210 East Grand Avenue, South San Francisco, United States

10xby3 Dec. 5 at 2:29 PM

$SLV $ALMS $ALLO $CHRS full force!

0 · Reply

tradersunion353 Dec. 5 at 3:14 AM

$ALLO Will be back under $1 Expect reverse split soon

0 · Reply

10xby3 Dec. 4 at 8:06 PM

$ALLO steady as she goes - 1.70s to 2s

0 · Reply

tradersunion353 Dec. 4 at 3:05 PM

$ALLO There is strong reason for insiders to sell this pos even at $1 range When ceo , cfo are sellling shares of the company they manage.. runaway

1 · Reply

tradersunion353 Dec. 3 at 10:41 PM

$ALLO Reverse split coming soon $50 to $1 HeaVy insider selling even at $1 range is no fun Scam

0 · Reply

mcrotary Dec. 3 at 8:54 PM

$ALLO came for a quick 5% scalp but the break a retest happening on the daily time frame looks strong.. lets hold till friday

0 · Reply

BeefandCheese Dec. 3 at 8:53 PM

$ALLO up

0 · Reply

mcrotary Dec. 3 at 6:37 PM

$ALLO $1.50+

0 · Reply

tradersunion353 Dec. 3 at 12:20 AM

$ALLO Reverse split coming soon 🚨🚨🚨🚨

0 · Reply

rlkloehn Dec. 1 at 6:13 PM

$ALLO We’re pleased to participate in the 37th Annual Piper Sandler Healthcare Conference tomorrow where our CEO and Co-Founder David Chang will share insights on our pipeline and corporate strategy. #CART Learn More About ALPHA3: https://lnkd.in/eT8WT9Ar

0 · Reply

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Nov 7, 2025, 6:08 PM EST - 27 days ago

Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T

Nov 7, 2025, 12:16 AM EST - 4 weeks ago

Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 weeks ago

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Nov 3, 2025, 9:04 AM EST - 4 weeks ago

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Oct 30, 2025, 8:30 AM EDT - 5 weeks ago

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Oct 4, 2025, 12:22 AM EDT - 2 months ago

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Aug 27, 2025, 8:30 AM EDT - 3 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 14, 2025, 3:02 PM EDT - 4 months ago

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Aug 13, 2025, 9:13 PM EDT - 4 months ago

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 4 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 6, 2025, 8:30 AM EDT - 4 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 1, 2025, 8:30 AM EDT - 4 months ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Jun 1, 2025, 10:45 AM EDT - 6 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

May 29, 2025, 3:37 PM EDT - 6 months ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 28, 2025, 9:43 AM EDT - 6 months ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 22, 2025, 5:17 PM EDT - 7 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 13, 2025, 10:47 PM EDT - 7 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 7 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 6, 2025, 8:30 AM EDT - 7 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Apr 23, 2025, 10:12 AM EDT - 8 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 7, 2025, 8:30 AM EDT - 8 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Mar 13, 2025, 11:56 PM EDT - 9 months ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 9 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 3, 2025, 8:30 AM EST - 9 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Feb 26, 2025, 10:52 AM EST - 10 months ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 8:30 AM EST - 10 months ago

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 25, 2025, 4:10 PM EST - 10 months ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 24, 2025, 10:53 PM EST - 10 months ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

$Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology$

Feb 13, 2025, 4:30 PM EST - 10 months ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Jan 28, 2025, 8:30 AM EST - 11 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dec 16, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Nov 19, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 18, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 7, 2024, 8:59 PM EST - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 5, 2024, 9:10 AM EST - 1 year ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Aug 26, 2024, 11:39 PM EDT - 1 year ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 10, 2024, 12:34 AM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 12, 2024, 1:09 PM EDT - 1 year ago

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

May 23, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

10xby3 Dec. 5 at 2:29 PM

$SLV $ALMS $ALLO $CHRS full force!

0 · Reply

tradersunion353 Dec. 5 at 3:14 AM

$ALLO Will be back under $1 Expect reverse split soon

0 · Reply

10xby3 Dec. 4 at 8:06 PM

$ALLO steady as she goes - 1.70s to 2s

0 · Reply

tradersunion353 Dec. 4 at 3:05 PM

$ALLO There is strong reason for insiders to sell this pos even at $1 range When ceo , cfo are sellling shares of the company they manage.. runaway

1 · Reply

tradersunion353 Dec. 3 at 10:41 PM

$ALLO Reverse split coming soon $50 to $1 HeaVy insider selling even at $1 range is no fun Scam

0 · Reply

mcrotary Dec. 3 at 8:54 PM

$ALLO came for a quick 5% scalp but the break a retest happening on the daily time frame looks strong.. lets hold till friday

0 · Reply

BeefandCheese Dec. 3 at 8:53 PM

$ALLO up

0 · Reply

mcrotary Dec. 3 at 6:37 PM

$ALLO $1.50+

0 · Reply

tradersunion353 Dec. 3 at 12:20 AM

$ALLO Reverse split coming soon 🚨🚨🚨🚨

0 · Reply

rlkloehn Dec. 1 at 6:13 PM

0 · Reply

vu_jade Nov. 24 at 8:57 PM

$ALLO add

0 · Reply

merlin8121 Nov. 22 at 6:35 AM

$ALLO https://www.youtube.com/shorts/_DSnrdOwvBg

0 · Reply

tradersunion353 Nov. 22 at 12:03 AM

$ALLO Entire market is up Meanwhile junkie is trading at $1.25 What a POS stock

1 · Reply

longrigger52 Nov. 18 at 5:00 PM

$ALLO i need this to stay in the 1.20s as i am still loading. trying to hustle to get to 100k shares but may not make it almost but need more time

0 · Reply

longrigger52 Nov. 13 at 9:21 PM

$ALLO check out fierce biotech’s article on new fda program called ”plausible pathway”. it is new program to speed up cell and gene therapy that treat unmet needs with personalized medicine. rather than use a sungle drug to treat a single disease, the program will approve the mechanism to apply to a variety if disease just as allo 329 is a basket design. allo is setting up to use this progra to speed to market they specifically me tioned autoimmune diseases

1 · Reply

AlexRo777 Nov. 13 at 2:34 PM

$ALLO so even with conference yesterday, this didn’t move a cent, and actually it’s going down, such a frustrating stock

0 · Reply

ChicagoJoe20 Nov. 13 at 12:34 PM

$CRBU gents, $IMMX and $ALLO. I won't suggest any in vivo companies yet. ;)

0 · Reply

OspreyFunds Nov. 12 at 4:23 PM

Weekly $BNB.X Update Gain exposure to $BNB.X with Osprey BNB Chain Trust (Ticker: $OBNB) MOOMOO LAUNCHES BNB TRADING IN U.S. AND SINGAPORE Moomoo has launched $BNB.X trading in the U.S. and Singapore, giving traditional investors a regulated entry to crypto. The move underscores growing efforts by brokerages to connect mainstream finance and digital assets. BINANCE AIRDROPS ALLO TO BNB STAKERS Binance added Allora ($ALLO), a decentralized AI network, to its HODLer Airdrops lineup, rewarding users who staked BNB in Simple Earn or On-Chain Yields. $ALLO is live on BNB Chain, Ethereum, and Base with 200.5M tokens in circulation. CONCORDIUM TO ENABLE AGE-VERIFIED PAYMENTS Concordium will launch identity-verified stablecoin payments to 75M Bitcoin wallets, including support for BNB Smart Chain. Using zero-knowledge proofs, it enables private, compliant payments for age-restricted products—marking a key step for BNB Chain in real-world crypto adoption.

0 · Reply

AlexRo777 Nov. 12 at 12:36 PM

$ALLO past month hasn’t moved at all, when XBI is at 52 weeks high, what a trash stock this is… hopefully something will happen from the conferences that they’re participating but very unlikely as always

1 · Reply

rlkloehn Nov. 10 at 2:18 PM

$ALLO We are looking forward to participating in the upcoming TD Cowen, Jefferies and Piper Sandler Healthcare investor conferences

0 · Reply

BioBuddha Nov. 7 at 6:44 PM

$ALLO this may be coming out of doghouse . No guarantees. But that’s how I feel right now

1 · Reply

ZacksResearch Nov. 7 at 6:35 PM

$ALLO just surprised with a narrower Q3 loss 👀 Loss came in at 19 cents per share, topping estimates as R&D and G&A costs dropped — impressive given there were no product sales. Full breakdown of the quarter here 👉 https://www.zacks.com/stock/news/2787959/allogene-posts-narrower-than-expected-loss-in-q3-nil-sales?cid=sm-stocktwits-2-2787959-teaser-20188&ADID=SYND_STOCKTWITS_TWEET_2_2787959_TEASER_20188

0 · Reply

Market Cap	301.14M
Revenue (ttm)	20,000.00
Net Income (ttm)	-257.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,287,950.01%
Debt to Equity Ratio	0.00

Volume	1,541,200
Avg Vol	2,704,396
Day's Range	N/A - N/A
Shares Out	224.73M
Stochastic %K	100%
Beta	0.47
Analysts	Strong Sell
Price Target	$7.56